No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
CHRS250117P4000
- 2.55
- 0.000.00%
15min DelayTrading Dec 19 13:43 ET
0.00High0.00Low
0.00Open2.55Pre Close0 Volume4 Open Interest4.00Strike Price0.00Turnover0.00%IV-1.40%PremiumJan 17, 2025Expiry Date2.57Intrinsic Value100Multiplier25DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.56Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Coherus To Present Randomized Phase 2 Study Evaluating The Combination Of Casdozokitug, Toripalimab And Bevacizumab In Patients With Liver Cancer
Biosimilars Market Industry Trends and Global Forecasts to 2035, Featuring Amgen, BIOCAD, Biocon, Celltrion, Coherus BioSciences, Eli Lilly, Fresenius Kabi, Pfizer, Sandoz and Teva Pharmaceuticals - ResearchAndMarkets.com
TD Cowen Reaffirms Their Buy Rating on Coherus Biosciences (CHRS)
Coherus BioSciences Price Target Raised to $6.00/Share From $4.00 by Baird
Coherus BioSciences Is Maintained at Outperform by Baird
Coherus Biosciences Announces Board Member Resignation